 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer
|
|
|
|
Phase III
|
|
|
|
DUMC-4516-04-2R1ER
DUMC-G030263, DUMC-4516031R0, NCT00085631
|
|
| |
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
|
|
|
|
Phase III
|
|
|
|
GOG-0219
GOG-0219, CAN-NCIC-GOG-0219, NCT00262821
|
|
| |
Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
|
|
|
|
Phase II
|
|
|
|
UTHSC-MS-96205
NCI-V97-1356, NCT00003135
|
|
| |
Tariquidar and Docetaxel in Treating Patients With Recurrent or Metastatic Lung, Ovarian, Cervical Cancer, or Kidney Cancer
|
|
|
|
Phase II
|
|
|
|
NCI-03-C-0284
NCT00072202
|
|
| |
Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma
|
|
|
|
Phase II
|
|
|
|
UCI 03-33
NCT00257816
|
|
| |
Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma
|
|
|
|
Phase II
|
|
|
|
05-0702
CA225243, NCT00292955
|
|
| |
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
|
|
|
|
Phase II
|
|
|
|
CINJ-3330
NCT00161187
|
|
| |
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
|
|
|
|
Phase II
|
|
|
|
06-1098
GSK 107278, NCT00548418
|
|
| |
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
|
|
|
|
Phase II
|
|
|
|
04-061
NCT00587964
|
|
| |
Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
|
|
|
|
Phase II
|
|
|
|
AVF3963s
NCT00600210
|
|
